Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence

Stefano Cianci, Carlo Ronsini, Giuseppe Vizzielli, Alessandro Tropea, Antonio Biondi, Giovanni Scambia, Anna Fagotti

Research output: Contribution to journalArticlepeer-review


Secondary and tertiary cytoreductive surgery was associated with improved overall survival in platinum-sensitive recurrent ovarian cancer (ROC). Hyperthermic intraoperative intra-peritoneal chemotherapy (HIPEC) is considered an attractive method in the treatment of ROC to deliver chemotherapy with enhanced effect directly at the tumor site. However, another deserving aspect is the feasibility and the oncologic role of HIPEC repetition. Twelve patients affected by secondary ovarian cancer recurrence previously submitted to cytoreduction followed by HIPEC were enrolled for the present study to receive tertiary cytoreduction followed by HIPEC repetition. The median operative time, including time for HIPEC procedure, was 360 min (range 240-540). Average EBL was 325 ml (from 100 to 500 ml). The median hospital stay was of 5 days, from 4 to 10. Low-grade post operatory complications occurred in 2 patients (16.6%) and high-grade complication in 1 case (8.3%). Our study report encouraging data about safety of HIPEC repetition in ovarian cancer treatment.

Original languageEnglish
JournalUpdates in Surgery
Publication statusE-pub ahead of print - Nov 8 2018


Dive into the research topics of 'Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence'. Together they form a unique fingerprint.

Cite this